An open-label Phase I dose-escalation study to evaluate the safety, tolerability, max. tolerated dose, pharmacokinetics,and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects w/ advanced solid tumors known to expressC4

Administered By

Awarded By

Contributors

Start/End

  • March 31, 2017 - October 14, 2019